Last updated on September 2018

Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation

Brief description of study

There are insufficient data on the safety and efficacy of edoxaban therapy in subjects with AF following catheter ablation. This phase 3b study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based antithrombotic regimen versus a VKA-based antithrombotic regimen in subjects with AF following catheter ablation. Bleeding is a central safety outcome in cardiovascular clinical trials, especially for antithrombotic strategies and invasive procedures.

Clinical Study Identifier: NCT02942576

Contact Investigators or Research Sites near you

Start Over

Site Coordinator

Policlinico Casilino
Roma, Italy

Site Coordinator

Largo Agostino Gemelli
Rome, Italy